Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B ...
Major Key player Arvinas announced completed Phase I and interim Phase II ARDENT data for ARV-110 degrader targeting the androgen receptor (AR). According to the results, Arvinas mentioned that at...
Preliminary findings of Phase I/II dose-expansion study of DS-7300 (a B7-H3 antibody-drug conjugate) in mCRPC patients backed B7-H3 as a potential new target in treatment-resistant prostate cancer...
The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals...
FDA approves IND application of Accutar for a prostate cancer treatment trial The US Food and Drug Administration (FDA) has granted Accutar Biotechnology’s Investigational New Drug (IND) applic...
Biogen-Eisai's potential Aduhelm sequel drug secured speedy review by FDA Biogen and Eisai’s Alzheimer’s disease treatment-in-waiting, lecanemab, has been secured a fast-track tag by the FDA, s...
Burn is a global public health problem, causing more than 180,000 deaths per year acros...
A Burn takes place when the skin comes into contact with a heat source. Burns can occur...
Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...
The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...
The organ on a chip is a microfluidic culture device that recapitulates the complicated...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.